Get a glimpse into our company and investor data—powered by the PitchBook Platform
A novel therapeutic technique approved for the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer.
This information is reserved for PitchBook Platform users. To explore Axcan (Photofrin and Photobarr)‘s full profile, request access.
© 2019 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.